PDCD1 and neoplasm: The combined treatment significantly delayed tumor growth and enhanced antitumoral immunity by lowering PD-1 expression levels in tumor-infiltrating CD4 T cells (Fig. 5g–j, Supplementary Fig. 7f–h) but not in CD4 T cells isolated from lymph nodes of tumor-bearing mice (Supplementary fig. 7i).